Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 432 participants.

Also called NCT07933692

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 432 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07933692
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07933692. Randomized; no masking; primary purpose treatment. Start 2021-10-01 (actual); primary completion 2026-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Edaravone
Intervention (Drug)
Edaravone Dexborneol
Lead sponsor
Shandong Provincial Hospital (class: other government)
Collaborator
Dongying People's Hospital (class: other)
Collaborator
Zibo Central Hospital (class: other government)
Collaborator
Heze Municipal Hospital (class: other)
Collaborator
Shengli Oilfield Hospital (class: other)
Collaborator
Liaocheng People's Hospital (class: other)
Collaborator
Tengzhou Central People's Hospital (class: other government)
Collaborator
Shandong Province Third hospital (class: other)
Collaborator
Zaozhuang Municipal Hospital (class: other)

Record details

Record id
cardio:ct-nct07933692
Content hash
df8bc6d1e620b544e00cf2608563a7efe39cbc5d632614639070f7083c2513d3